Coro Bescós - Academia.edu (original) (raw)

Papers by Coro Bescós

Revista Española de Cirugía Oral y Maxilofacial, 2012

El ameloblastoma es un tumor odontogénico de estirpe epitelial. Aunque se clasifica como una tumo... more El ameloblastoma es un tumor odontogénico de estirpe epitelial. Aunque se clasifica como una tumoración benigna, suele ser localmente agresiva presentando elevada invasión local, con gran tendencia a la recidiva y con posibilidad metastásica ocasional. Se manifiesta preferentemente durante la tercera, cuarta y quinta décadas de la vida, sin predilección por razón de sexo, aunque puede darse en cualquier grupo de edad, incluidos los niños. La mayoría de los ameloblastomas se encuentran sobre todo en mandíbula (al nivel del ángulo y rama). En el tratamiento se debe valorar su tipología clínica (sólido, multiquístico, uniquístico, mixto o periférico), su localización y el tamaño del tumor, así como la edad y las condiciones clínicas del paciente. Presentamos una revisión de los pacientes afectos de ameloblastomas tratados en nuestro Centro durante los últimos 10 años. Se aportan datos acerca de su aparición clínica, sus características histológicas, el manejo terapéutico realizado y analizamos el seguimiento y comparamos la aparición de recidivas en los pacientes presentados. Las características clínicas, incluso si se complementan con radiografías y/o muestras histológicas, no son siempre determinantes del comportamiento biológico y, por tanto tampoco lo son del pronóstico de un ameloblastoma individual.

espanolEl fibrosarcoma ameloblastico es un infrecuente tumor odontogenico maligno que se caracter... more espanolEl fibrosarcoma ameloblastico es un infrecuente tumor odontogenico maligno que se caracteriza por la presencia de un componente epitelial benigno en un estroma fibroso maligno, con buen comportamiento clinico y buen pronostico, sin producir metastasis. Es un tumor paradojico con patron morfologico e inmunohistoquimico tipico de sarcoma, pero que se comporta como un tumor benigno. En este trabajo aportamos un nuevo caso de este tumor que afectaba la mandibula de un varon de 31 anos y que, tras la extirpacion quirurgica y un tratamiento quimio y radioterapico, ha remitido totalmente a los 5 anos. Estudiamos su potencial de crecimiento y lo comparamos con otro tumor de la misma especie, el fibroma ameloblastico. El fibrosarcoma ameloblastico muestra positividad intensa a Ki-67, PCNA y p53 en su componente mesenquimal, mientras que en el fibroma ameloblastico estos marcadores son negativos. EnglishAmeloblastic fibrosarcoma is a rare malignant odontogenic tumour characterized by a...

British Journal of Surgery, 2021

Background Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numb... more Background Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18–49, 50–69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results NNVs were more favourable in surgical patients than the general population. The most favourable NNVs were in patients aged 70 years or more needing cancer surgery (351; best case 196, worst case 816) or non-cancer surgery (733; best case 407, worst case 1664). Both exceeded the NNV in the general population (1840; best case 1196, worst ...

Journal of Clinical Oncology

6031 Background: Multiple genomic alterations were described in HNC, including squamous cell carc... more 6031 Background: Multiple genomic alterations were described in HNC, including squamous cell carcinomas (SCC), salivary gland (SG) and nasopharyngeal (NF) tumors. Tumor molecular profiling (TMP) may increase therapeutic alternatives in early trials for pts with refractory metastatic (met) HNC. We evaluate the impact of matched/unmatched therapy (mT/uT) in HNC with potentially targetable alterations. Methods: From 2010-16, 47 met HNC pts were treated in 57 early trials after TMP. Clinical benefit was measured by: time to progression (TTP); clinical benefit rate (CBR: complete response [CR], partial response [PR] and stable disease [SD] > 4months [m]); progression-free survival [PFS] ratio≥1.3 (PFS under molecular therapeutics/PFS upon last prior chemotherapy [pT]). Results: Median age was 51 years; median number of pT lines was 1 (0-5). In total, 26 SCC, 11 SG, 8 NF and 2 nasosinusal pts (mostly with lymph nodes and lung met) were treated with small kinases (SK) inhibitors (inh) (...

Journal of Clinical Oncology

6030Background: HNC encompass a group of highly heterogeneous diseases, including oral, oropharyn... more 6030Background: HNC encompass a group of highly heterogeneous diseases, including oral, oropharyngeal and laryngeal squamous cell carcinomas (SCC), nasopharyngeal (NP), nasosinusal (NS) and salivary gland (SG) tumors. Chemotherapy has shown limited efficacy in recurrent (rec)/metastatic (met) disease. Genomic studies have increased our understanding of HNC biology, identifying potential targetable mutations (mut). We evaluated the impact of precision medicine efforts in HNC at Vall d’Hebron Institute of Oncology (VHIO). Methods: From 10/2010 to 10/2015, 49 patients (pts) with metastatic HNC underwent tumor molecular profiling at VHIO. Mut detection was performed using multiplex mass-spectrometry (Sequenom, n = 21) or NGS (AmpliconSeq, n = 28).Profiling was performed on metastatic (n = 21) or primary sites (n = 19), with missing information in remaining cases (n = 9). Results: Most frequent tumor type was SCC (n = 20), followed by SG (n = 18), NP (n = 9) and NS (n = 2). Median age at diagnosis was 51 years...

recipient and donor sites were documented and clinical outcomes were assessed. Results: A total o... more recipient and donor sites were documented and clinical outcomes were assessed. Results: A total of 11 cases of mandibular reconstruction have been done in ten patients. Six (60%) of them are females and 4 (40%) are males. The age range was between 19 and 61 years. Primary reconstruction with both iliac bone graft and plate were done in 3 patients, primary reconstruction with iliac bone graft only and secondary reconstruction with both rib graft and plate in 1 patient, primary reconstruction with only iliac bone in 5 patients and, primary reconstruction with Steinman's pin in 1 patient. Conclusion: All bone grafts were non vascularized and there was 100% take. Conflict of interest: None declared.

Radiotherapy and Oncology, 2012

Nature, Jan 5, 2017

The fact that the identity of the cells that initiate metastasis in most human cancers is unknown... more The fact that the identity of the cells that initiate metastasis in most human cancers is unknown hampers the development of antimetastatic therapies. Here we describe a subpopulation of CD44(bright) cells in human oral carcinomas that do not overexpress mesenchymal genes, are slow-cycling, express high levels of the fatty acid receptor CD36 and lipid metabolism genes, and are unique in their ability to initiate metastasis. Palmitic acid or a high-fat diet specifically boosts the metastatic potential of CD36(+) metastasis-initiating cells in a CD36-dependent manner. The use of neutralizing antibodies to block CD36 causes almost complete inhibition of metastasis in immunodeficient or immunocompetent orthotopic mouse models of human oral cancer, with no side effects. Clinically, the presence of CD36(+) metastasis-initiating cells correlates with a poor prognosis for numerous types of carcinomas, and inhibition of CD36 also impairs metastasis, at least in human melanoma- and breast can...

Head & Neck, 2016

The best treatment for advanced tongue tumors remains controversial. Total glossectomy with laryn... more The best treatment for advanced tongue tumors remains controversial. Total glossectomy with laryngeal preservation is considered a feasible option, despite its morbidity. A retrospective analysis of 12 total glossectomies with laryngeal preservation was performed in order to assess the available reconstruction techniques and analyze survival and functional outcomes. One-year overall survival (OS) and disease-free survival (DFS) rates were 58.3% and 33.3%, respectively, both dropping to 25% after 3 years. Permanent gastrostomy was necessary in 10 patients, although videofluoroscopy revealed adequate tolerance to liquids. Speech intelligibility was satisfactory in 50% of the patients and severely impaired in the remaining 50%. Laryngeal preservation in the context of advanced tumors of the tongue without supraglottic invasion carried similar oncologic results to total glossectomy with laryngectomy, but offers a better phonatory function. However, it is usually associated with a higher gastrostomy dependency ratio. A scrupulous selection of candidates is mandatory. © 2016 Wiley Periodicals, Inc. Head Neck, 2016.

International Journal of Oral and Maxillofacial Surgery, 2011

Knowledge of the presence and degree of extend of bone infiltration is crucial for planning resec... more Knowledge of the presence and degree of extend of bone infiltration is crucial for planning resection of potential bone infiltrating squamous cell carcinomas of the head and neck region. Routinely, plain film radiography, CT and MRI are used for preoperative staging, but go along with a relatively high rate of false

Radiotherapy and Oncology, 1996

Journal of Oral and Maxillofacial Surgery, 1995

Merkel cell tumor (MCT) is an infrequent but aggressive neuroendocrine skin lesion. Four hundred ... more Merkel cell tumor (MCT) is an infrequent but aggressive neuroendocrine skin lesion. Four hundred cases have been reported in the literature. The largest published series includes 70 cases treated between 1968 and 1989 in the Memorial Sloan-Kettering Cancer Center.' MCT was originally described by Tacker in 1972 as a trabecular tumor of the sweat glands. The name Merkel cell tumor was assigned in 1978 when Tang and Tacker,' using an electron microscope, observed dense granules in the cytoplasm similar to those seen in Merkel cells. The Merkel cell is a tactile receptor found in the basal layers of the epidermis of certain areas of the skin such as the lips, the external sheaths of the hair follicles, the fingertips, and the oral cavity. The typical presentation is as a painless, well-defined nodular lesion, rarely ulcerated, with a pink or violet color, located in the subcutaneous region of the dermis; the epidermis is generally preserved. It is seen most frequently in white women (60%) with an average age of between 60 and 70 years (range, 23 to 96 years). Sunlight exposure is common in the history. The most frequent location is in the head and neck (46% of cases), followed by the limbs (42%), and the trunk (10%). Only one intraoral case has been reported. The MCT appears as a single nodule in 70% to 80% of cases, while 20% to 25% show initial lymphatic node infiltration. Only 1% to 2% show systemic metastasis and such cases are usually associated with the liver, followed by the bones, brain, lungs, and skin." Ninety percent of cases of metastasis appear within the first 2 years after diagnosis. MCT has been described in association with other tumors: basal cell carcinoma, squamous cell carcinoma, lymphoma, chronic lymphatic leukemia, and adenocarcinoma of the pancreas.4~s-'8 The ability of the

Journal of Oral and Maxillofacial Surgery, 1996

Journal of Cranio-Maxillofacial Surgery, 2008

American Journal of Clinical Oncology, 1997

Combined chemoradiotherapy (CT/RT) treatments appear to yield better results for advanced tumours... more Combined chemoradiotherapy (CT/RT) treatments appear to yield better results for advanced tumours of the head and neck than do conventional therapies. In the present study, CT/RT was used preoperatively in unresectable tumors of the oral cavity and oropharynx. Forty patients were entered prospectively into a phase II study. Treatment consisted of three cycles of chemotherapy with cisplatin and 5-day infusion of fluorouracil (FU), and the addition of simultaneous radiotherapy (30 Gy) from the second to third cycles. Patients with resectable residual disease or complete clinical response underwent surgery. All patients later received a second phase of irradiation (30 Gy) and two cycles of chemotherapy only in responders. During the first phase of treatment, 22 (55%) patients presented mucositis grades III-IV. Mean weight loss was 7%. Twelve patients were admitted for parenteral nutrition. Thirty-six (90%) patients obtained clinical response, which was complete in 15 (37%). Thirty-two of the 40 underwent surgery. The percentage of pathologic complete responses (PCR) was 35% (14 patients). With a median follow-up of 21 months, the median survival of patients was 23 months, and 19 (47%) of them are disease-free. A high PCR rate was attained with this treatment regimen. Toxicity was significant, but tolerable with adequate support measures.

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2015

Revista Española de Cirugía Oral y Maxilofacial, 2012

ABSTRACT The ameloblastoma is an odontogenic tumour of epithelial origin. Although it is classifi... more ABSTRACT The ameloblastoma is an odontogenic tumour of epithelial origin. Although it is classified as benign, there is usually aggressive local invasion, a great tendency to recurrence, and occasional metastatic potential. It generally appears during the third, fourth and fifth decades of life, without gender predilection, although it can occur at any age, including in children. Ameloblastomas are mostly found in the mandible (angle and branch). In treatment, its clinical type (solid, unicystic, desmoplastic, mixed or peripheral), its location and size, must be assessed, as well as the age and clinical condition of the patient. We present a review of patients diagnosed and treated for ameloblastoma in our hospital during the last 10 years. We present data on clinical appearance, histological characteristics, and therapeutic management, and we analyse and compare the rate of recurrence in these patients. The clinical features, even if they are supplemented with radiographs and/or histological samples, are not always biological determinants of its behaviour, or of the individual prognosis of the ameloblastoma.

Revista Española de Cirugía Oral y Maxilofacial, 2012

El ameloblastoma es un tumor odontogénico de estirpe epitelial. Aunque se clasifica como una tumo... more El ameloblastoma es un tumor odontogénico de estirpe epitelial. Aunque se clasifica como una tumoración benigna, suele ser localmente agresiva presentando elevada invasión local, con gran tendencia a la recidiva y con posibilidad metastásica ocasional. Se manifiesta preferentemente durante la tercera, cuarta y quinta décadas de la vida, sin predilección por razón de sexo, aunque puede darse en cualquier grupo de edad, incluidos los niños. La mayoría de los ameloblastomas se encuentran sobre todo en mandíbula (al nivel del ángulo y rama). En el tratamiento se debe valorar su tipología clínica (sólido, multiquístico, uniquístico, mixto o periférico), su localización y el tamaño del tumor, así como la edad y las condiciones clínicas del paciente. Presentamos una revisión de los pacientes afectos de ameloblastomas tratados en nuestro Centro durante los últimos 10 años. Se aportan datos acerca de su aparición clínica, sus características histológicas, el manejo terapéutico realizado y analizamos el seguimiento y comparamos la aparición de recidivas en los pacientes presentados. Las características clínicas, incluso si se complementan con radiografías y/o muestras histológicas, no son siempre determinantes del comportamiento biológico y, por tanto tampoco lo son del pronóstico de un ameloblastoma individual.

espanolEl fibrosarcoma ameloblastico es un infrecuente tumor odontogenico maligno que se caracter... more espanolEl fibrosarcoma ameloblastico es un infrecuente tumor odontogenico maligno que se caracteriza por la presencia de un componente epitelial benigno en un estroma fibroso maligno, con buen comportamiento clinico y buen pronostico, sin producir metastasis. Es un tumor paradojico con patron morfologico e inmunohistoquimico tipico de sarcoma, pero que se comporta como un tumor benigno. En este trabajo aportamos un nuevo caso de este tumor que afectaba la mandibula de un varon de 31 anos y que, tras la extirpacion quirurgica y un tratamiento quimio y radioterapico, ha remitido totalmente a los 5 anos. Estudiamos su potencial de crecimiento y lo comparamos con otro tumor de la misma especie, el fibroma ameloblastico. El fibrosarcoma ameloblastico muestra positividad intensa a Ki-67, PCNA y p53 en su componente mesenquimal, mientras que en el fibroma ameloblastico estos marcadores son negativos. EnglishAmeloblastic fibrosarcoma is a rare malignant odontogenic tumour characterized by a...

British Journal of Surgery, 2021

Background Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numb... more Background Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18–49, 50–69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results NNVs were more favourable in surgical patients than the general population. The most favourable NNVs were in patients aged 70 years or more needing cancer surgery (351; best case 196, worst case 816) or non-cancer surgery (733; best case 407, worst case 1664). Both exceeded the NNV in the general population (1840; best case 1196, worst ...

Journal of Clinical Oncology

6031 Background: Multiple genomic alterations were described in HNC, including squamous cell carc... more 6031 Background: Multiple genomic alterations were described in HNC, including squamous cell carcinomas (SCC), salivary gland (SG) and nasopharyngeal (NF) tumors. Tumor molecular profiling (TMP) may increase therapeutic alternatives in early trials for pts with refractory metastatic (met) HNC. We evaluate the impact of matched/unmatched therapy (mT/uT) in HNC with potentially targetable alterations. Methods: From 2010-16, 47 met HNC pts were treated in 57 early trials after TMP. Clinical benefit was measured by: time to progression (TTP); clinical benefit rate (CBR: complete response [CR], partial response [PR] and stable disease [SD] > 4months [m]); progression-free survival [PFS] ratio≥1.3 (PFS under molecular therapeutics/PFS upon last prior chemotherapy [pT]). Results: Median age was 51 years; median number of pT lines was 1 (0-5). In total, 26 SCC, 11 SG, 8 NF and 2 nasosinusal pts (mostly with lymph nodes and lung met) were treated with small kinases (SK) inhibitors (inh) (...

Journal of Clinical Oncology

6030Background: HNC encompass a group of highly heterogeneous diseases, including oral, oropharyn... more 6030Background: HNC encompass a group of highly heterogeneous diseases, including oral, oropharyngeal and laryngeal squamous cell carcinomas (SCC), nasopharyngeal (NP), nasosinusal (NS) and salivary gland (SG) tumors. Chemotherapy has shown limited efficacy in recurrent (rec)/metastatic (met) disease. Genomic studies have increased our understanding of HNC biology, identifying potential targetable mutations (mut). We evaluated the impact of precision medicine efforts in HNC at Vall d’Hebron Institute of Oncology (VHIO). Methods: From 10/2010 to 10/2015, 49 patients (pts) with metastatic HNC underwent tumor molecular profiling at VHIO. Mut detection was performed using multiplex mass-spectrometry (Sequenom, n = 21) or NGS (AmpliconSeq, n = 28).Profiling was performed on metastatic (n = 21) or primary sites (n = 19), with missing information in remaining cases (n = 9). Results: Most frequent tumor type was SCC (n = 20), followed by SG (n = 18), NP (n = 9) and NS (n = 2). Median age at diagnosis was 51 years...

recipient and donor sites were documented and clinical outcomes were assessed. Results: A total o... more recipient and donor sites were documented and clinical outcomes were assessed. Results: A total of 11 cases of mandibular reconstruction have been done in ten patients. Six (60%) of them are females and 4 (40%) are males. The age range was between 19 and 61 years. Primary reconstruction with both iliac bone graft and plate were done in 3 patients, primary reconstruction with iliac bone graft only and secondary reconstruction with both rib graft and plate in 1 patient, primary reconstruction with only iliac bone in 5 patients and, primary reconstruction with Steinman's pin in 1 patient. Conclusion: All bone grafts were non vascularized and there was 100% take. Conflict of interest: None declared.

Radiotherapy and Oncology, 2012

Nature, Jan 5, 2017

The fact that the identity of the cells that initiate metastasis in most human cancers is unknown... more The fact that the identity of the cells that initiate metastasis in most human cancers is unknown hampers the development of antimetastatic therapies. Here we describe a subpopulation of CD44(bright) cells in human oral carcinomas that do not overexpress mesenchymal genes, are slow-cycling, express high levels of the fatty acid receptor CD36 and lipid metabolism genes, and are unique in their ability to initiate metastasis. Palmitic acid or a high-fat diet specifically boosts the metastatic potential of CD36(+) metastasis-initiating cells in a CD36-dependent manner. The use of neutralizing antibodies to block CD36 causes almost complete inhibition of metastasis in immunodeficient or immunocompetent orthotopic mouse models of human oral cancer, with no side effects. Clinically, the presence of CD36(+) metastasis-initiating cells correlates with a poor prognosis for numerous types of carcinomas, and inhibition of CD36 also impairs metastasis, at least in human melanoma- and breast can...

Head & Neck, 2016

The best treatment for advanced tongue tumors remains controversial. Total glossectomy with laryn... more The best treatment for advanced tongue tumors remains controversial. Total glossectomy with laryngeal preservation is considered a feasible option, despite its morbidity. A retrospective analysis of 12 total glossectomies with laryngeal preservation was performed in order to assess the available reconstruction techniques and analyze survival and functional outcomes. One-year overall survival (OS) and disease-free survival (DFS) rates were 58.3% and 33.3%, respectively, both dropping to 25% after 3 years. Permanent gastrostomy was necessary in 10 patients, although videofluoroscopy revealed adequate tolerance to liquids. Speech intelligibility was satisfactory in 50% of the patients and severely impaired in the remaining 50%. Laryngeal preservation in the context of advanced tumors of the tongue without supraglottic invasion carried similar oncologic results to total glossectomy with laryngectomy, but offers a better phonatory function. However, it is usually associated with a higher gastrostomy dependency ratio. A scrupulous selection of candidates is mandatory. © 2016 Wiley Periodicals, Inc. Head Neck, 2016.

International Journal of Oral and Maxillofacial Surgery, 2011

Knowledge of the presence and degree of extend of bone infiltration is crucial for planning resec... more Knowledge of the presence and degree of extend of bone infiltration is crucial for planning resection of potential bone infiltrating squamous cell carcinomas of the head and neck region. Routinely, plain film radiography, CT and MRI are used for preoperative staging, but go along with a relatively high rate of false

Radiotherapy and Oncology, 1996

Journal of Oral and Maxillofacial Surgery, 1995

Merkel cell tumor (MCT) is an infrequent but aggressive neuroendocrine skin lesion. Four hundred ... more Merkel cell tumor (MCT) is an infrequent but aggressive neuroendocrine skin lesion. Four hundred cases have been reported in the literature. The largest published series includes 70 cases treated between 1968 and 1989 in the Memorial Sloan-Kettering Cancer Center.' MCT was originally described by Tacker in 1972 as a trabecular tumor of the sweat glands. The name Merkel cell tumor was assigned in 1978 when Tang and Tacker,' using an electron microscope, observed dense granules in the cytoplasm similar to those seen in Merkel cells. The Merkel cell is a tactile receptor found in the basal layers of the epidermis of certain areas of the skin such as the lips, the external sheaths of the hair follicles, the fingertips, and the oral cavity. The typical presentation is as a painless, well-defined nodular lesion, rarely ulcerated, with a pink or violet color, located in the subcutaneous region of the dermis; the epidermis is generally preserved. It is seen most frequently in white women (60%) with an average age of between 60 and 70 years (range, 23 to 96 years). Sunlight exposure is common in the history. The most frequent location is in the head and neck (46% of cases), followed by the limbs (42%), and the trunk (10%). Only one intraoral case has been reported. The MCT appears as a single nodule in 70% to 80% of cases, while 20% to 25% show initial lymphatic node infiltration. Only 1% to 2% show systemic metastasis and such cases are usually associated with the liver, followed by the bones, brain, lungs, and skin." Ninety percent of cases of metastasis appear within the first 2 years after diagnosis. MCT has been described in association with other tumors: basal cell carcinoma, squamous cell carcinoma, lymphoma, chronic lymphatic leukemia, and adenocarcinoma of the pancreas.4~s-'8 The ability of the

Journal of Oral and Maxillofacial Surgery, 1996

Journal of Cranio-Maxillofacial Surgery, 2008

American Journal of Clinical Oncology, 1997

Combined chemoradiotherapy (CT/RT) treatments appear to yield better results for advanced tumours... more Combined chemoradiotherapy (CT/RT) treatments appear to yield better results for advanced tumours of the head and neck than do conventional therapies. In the present study, CT/RT was used preoperatively in unresectable tumors of the oral cavity and oropharynx. Forty patients were entered prospectively into a phase II study. Treatment consisted of three cycles of chemotherapy with cisplatin and 5-day infusion of fluorouracil (FU), and the addition of simultaneous radiotherapy (30 Gy) from the second to third cycles. Patients with resectable residual disease or complete clinical response underwent surgery. All patients later received a second phase of irradiation (30 Gy) and two cycles of chemotherapy only in responders. During the first phase of treatment, 22 (55%) patients presented mucositis grades III-IV. Mean weight loss was 7%. Twelve patients were admitted for parenteral nutrition. Thirty-six (90%) patients obtained clinical response, which was complete in 15 (37%). Thirty-two of the 40 underwent surgery. The percentage of pathologic complete responses (PCR) was 35% (14 patients). With a median follow-up of 21 months, the median survival of patients was 23 months, and 19 (47%) of them are disease-free. A high PCR rate was attained with this treatment regimen. Toxicity was significant, but tolerable with adequate support measures.

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2015

Revista Española de Cirugía Oral y Maxilofacial, 2012

ABSTRACT The ameloblastoma is an odontogenic tumour of epithelial origin. Although it is classifi... more ABSTRACT The ameloblastoma is an odontogenic tumour of epithelial origin. Although it is classified as benign, there is usually aggressive local invasion, a great tendency to recurrence, and occasional metastatic potential. It generally appears during the third, fourth and fifth decades of life, without gender predilection, although it can occur at any age, including in children. Ameloblastomas are mostly found in the mandible (angle and branch). In treatment, its clinical type (solid, unicystic, desmoplastic, mixed or peripheral), its location and size, must be assessed, as well as the age and clinical condition of the patient. We present a review of patients diagnosed and treated for ameloblastoma in our hospital during the last 10 years. We present data on clinical appearance, histological characteristics, and therapeutic management, and we analyse and compare the rate of recurrence in these patients. The clinical features, even if they are supplemented with radiographs and/or histological samples, are not always biological determinants of its behaviour, or of the individual prognosis of the ameloblastoma.